Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Some recent studies have not been able to support claims that human growth hormone can improve the athletic performance of professional male athletes. Athletes in many sports have used human growth hormone in order to attempt to enhance their athletic performance. One survey of adults that had been treated with replacement cadaver GH (which has not been used anywhere in the world since 1985) during childhood showed a mildly increased incidence of colon cancer and prostate cancer, but linkage with the GH treatment was not established. In 2019, the TRIIM trial paper showed that recombinant human growth hormone restores thymus function, improving the immune system and risk indices for many age‐related diseases. No other critical factors were affected, such as bone density, cholesterol levels, lipid measurements, maximal oxygen consumption, or any other factor that would indicate increased fitness.
A hormone (from Ancient Greek ὁρμῶν (hormôn) 'setting in motion') is a class of signaling molecules in multicellular organisms that are sent to distant organs or tissues by complex biological processes to regulate physiology and behavior. However, because GH is a potent endogenous protein, it is very difficult to detect GH doping. This has led to organizations such as the controversial American Academy of Anti-Aging Medicine promoting the use of this hormone as an "anti-aging agent". Claims for GH as an anti-aging treatment date back to 1990 when the New England Journal of Medicine published a study wherein GH was used to treat 12 men over 60. Examples of other causes of shortness often treated with GH are Turner syndrome, Growth failure secondary to chronic kidney disease in children, Prader–Willi syndrome, intrauterine growth restriction, and severe idiopathic short stature.
Genentech pioneered the use of recombinant human growth hormone for human therapy, which was approved by the FDA in 1985.citation needed Researchers also did not discover any gain in muscle strength, which led them to believe that GH merely let the body store more water in the muscles rather than increase muscle growth. At the conclusion of the study, all the men showed statistically significant increases in lean body mass and bone mineral density, while the control group did not. In these patients, benefits have variably included reduced fat mass, increased lean mass, increased bone density, improved lipid profile, reduced cardiovascular risk factors, and improved psychosocial well-being. Adults with GHD "tend to have a relative increase in fat mass and a relative decrease in muscle mass and, in many instances, decreased energy and quality of life". The effects of growth hormone (GH) deficiency vary depending on the age at which they occur. Effects of growth hormone on the tissues of the body can generally be described as anabolic (building up).
This suggests that intrinsic secretion (i.e. autocrine) of muscle IGF-1, beside circulating IGF-1, may be a determinant for switching on anabolic pathways (Morton et al., 2018) and fusion of satellite cells (Velloso, 2008). Indeed, circulating IGF-1 levels have even been shown to decrease during periods of active muscle building, likely due to a redistribution of IGF-1 from the circulation into the muscle (Arnarson et al., 2015). Like testosterone levels, older adults experience a lower basal level of IGF-1 (the so-called somatopause which refers to the diminishment of the GH-IGF-1 system) which attenuates post-RE levels of IGF-1 (Kraemer et al., 1999).
Prolonged GH excess thickens the bones of the jaw, fingers and toes, resulting in heaviness of the jaw and increased size of digits, referred to as acromegaly. Eventually, the adenoma may become large enough to cause headaches, impair vision by pressure on the optic nerves, or cause deficiency of other pituitary hormones by displacement.citation needed Like most other peptide hormones, GH acts by interacting with a specific receptor on the surface of cells.citation needed
When testosterone binds to the AR, the AR transforms, dimerizes and translocates to the nucleus, binding to androgen-response elements (ARE) therein, as a homodimer. Anabolic effects of AR and testosterone upregulation after RE occur through a combination of both genomic i.e., transcriptional capacity, and non-genomic i.e., translational efficiency, pathways (Kraemer et al., 2020). Moreover, females do not have Leydig cells; the cells which are likely the source of the acute RE-induced increase in testosterone in men (Kvorning et al., 2007). These differences may be important since the duration and magnitude of testosterone and AR elevation and AR exposure to testosterone appear to play a crucial role in skeletal muscle adaptations both in vitro (Bloomer et al., 2000) and in vivo (Antonio et al., 1999; Ferrando et al., 2002). Homeostatic processes maintain systemic testosterone levels within the range of 7.7–29.4 nmol.L−1 in healthy young men and 0.1–1.7 nmol.L−1 in healthy menstruating women under 40 y (Handelsman et al., 2018). The principal androgen, testosterone, is an anabolic-androgenic steroid hormone which is synthesized from cholesterol—produced mainly in Leydig cells in men, and the ovary (25%) and adrenalzona fasciculata (25%) in women, via conversion from progesterone, with the remaining ~50% being produced from circulating androstenedione (Burger, 2002).
While GH replacement therapy has been proposed to treat depression as a result of GH deficiency, the long-term effects of such therapy are unknown. In adults, somatomedin alteration contributes to increased osteoclast activity, resulting in weaker bones that are more prone to pathologic fracture and osteoporosis. Other drugs like octreotide (somatostatin agonist) and bromocriptine (dopamine agonist) can be used to block GH secretion because both somatostatin and dopamine negatively inhibit GHRH-mediated GH release from the anterior pituitary. Accompanying problems can include sweating, pressure on nerves (e.g., carpal tunnel syndrome), muscle weakness, excess sex hormone-binding globulin (SHBG), insulin resistance or even a rare form of type 2 diabetes, and reduced sexual function.citation needed
In an attempt to better understand the discrepancies between testosterone and muscle adaptive responses, Phillips and colleagues devised a unique experimental approach, whereby they compared a "high" vs. "low" hormone environment (induced by working distinct muscle bulk) (West et al., 2010). It seems high intensity RE stimulates basophilic cells of the anterior pituitary to release luteinizing hormone (LH) from gonadotrophs in the anterior pituitary which then acts as the primary regulator of testosterone secretion from the Leydig cells of the testes (Fry and Kraemer, 1997). For example, immediately following RE, serum testosterone levels peak ~from 13 (resting levels) to 38 (at ~30 mins) nmol.L−1 with a concomitant upregulation of AR mRNA and protein content within the muscle (Willoughby and Taylor, 2004; Hooper et al., 2017). RE has been shown to increase the concentration of these hormones which activate several different signaling pathways in the muscle.

Gender: Female

Social links